Section Arrow
COGT.NASDAQ
- Cogent Biosciences
Quotes are at least 15-min delayed:2025/07/21 06:55 EDT
Pre Market
Last
 12.73
+0.24 (+1.92%)
Bid
12.5
Ask
12.93
High 12.9 
Low 12.48 
Volume 475 
Regular Hours
Last
 12.49
+0.29 (+2.38%)
Day High 
12.95 
Prev. Close
12.2 
1-M High
12.515 
Volume 
3.68M 
Bid
12.5
Ask
12.93
Day Low
12.31 
Open
12.47 
1-M Low
6.92 
Market Cap 
1.70B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 10.56 
20-SMA 8.89 
50-SMA 6.97 
52-W High 12.95 
52-W Low 3.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.97/-2.93
Enterprise Value
1.72B
Balance Sheet
Book Value Per Share
0.80
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 1.98 -0.3 -13.16%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.05 -1.025 -7.28%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.28 +0.44 +7.53%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.1 +0.18 +3.04%
Quotes are at least 15-min delayed:2025/07/21 06:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.